Sorrento Therapeutics and Celularity Aim to Adapt Natural Killer Cell Therapy to Treat Coronavirus

Sorrento Therapeutics (NASDAQ: SRNE) and privately held Celularity announced Wednesday that they are collaborating to develop a natural killer (NK) cell therapy to treat and prevent coronavirus infections, especially the recent outbreak of 2019-nCoV in China. Sorrento's shareholders seem to think the biotech might be spreading itself a little thin with the added program -- its share price had fallen 6.7% as of 11:43 a.m. EST.